Dongsheng locks in selected Chinese rights to thymosin alpha-1 product
This article was originally published in Scrip
Executive Summary
The Chinese manufacturer Shanghai Biochemistry Pharmaceutical has granted Dongsheng Pharmaceutical International exclusive sales rights in 19 provinces in China to its thymosin alpha-1 product.